Want to see GB:ABDX full AI Analyst Report?
Top Page
Abingdon Health PLC
(LSE:ABDX)
Select Model
Select Model
Rating:50Neutral
Price Target:
10.50 p
▼(-4.55% Downside)
Action:Reiterated
Date:05/07/26
The score is held back primarily by weak financial quality—ongoing losses, declining gross margin, and negative operating cash flow—despite strong revenue growth. Technicals are supportive with the price above major moving averages and a positive MACD, but elevated RSI indicates potential near-term overheating. Valuation is constrained by negative earnings and the absence of a dividend yield.
Positive Factors
Revenue Growth
Sustained revenue growth of ~23.6% indicates expanding commercial traction in rapid diagnostics and growing demand for its services. Over a 2-6 month horizon this supports backlog visibility, scale benefits in manufacturing and strengthens commercial positioning versus peers.
Negative Factors
Negative Profitability
Persistent negative net profit and EBIT margins show the business is not converting sales into sustainable earnings. Without margin recovery, retained earnings remain constrained, limiting self-funding for growth and increasing reliance on external capital over months.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained revenue growth of ~23.6% indicates expanding commercial traction in rapid diagnostics and growing demand for its services. Over a 2-6 month horizon this supports backlog visibility, scale benefits in manufacturing and strengthens commercial positioning versus peers.
Read all positive factors
Abingdon Health PLC (ABDX) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£27.80M
Dividend YieldN/A
Average Volume (3M)108.35K
Price to Earnings (P/E)―
Beta (1Y)-0.03
Revenue Growth40.37%
EPS Growth-13.70%
CountryUK
Employees113
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding252,751,500
10 Day Avg. Volume91,800
30 Day Avg. Volume108,350
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)4.84
Price to Sales (P/S)3.04
P/FCF Ratio-7.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)£15.20M
Abingdon Health PLC Business Overview & Revenue Model
Company Description
Established in 2008 and based in York, United Kingdom, Abingdon Health Plc is a global entity dedicated to the creation, production, and worldwide distribution of diagnostic instruments. Their product line features the AbC-19 Rapid Test, a fast-ac...
How the Company Makes Money
Abingdon Health primarily makes money through providing contract services and manufacturing within the rapid diagnostics value chain. Its core revenue model is business-to-business, generating income by (1) developing rapid test assays for custome...
Abingdon Health PLC Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
50
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.57M | 8.43M | 6.13M | 4.04M | 2.83M | 11.62M |
| Gross Profit | 3.27M | 3.13M | 3.68M | 1.40M | -5.23M | 3.39M |
| EBITDA | -2.98M | -3.12M | -916.00K | -2.81M | -19.98M | -6.07M |
| Net Income | -3.24M | -3.42M | -1.27M | -3.47M | -21.26M | -6.97M |
Balance Sheet | ||||||
| Total Assets | 10.55M | 9.31M | 5.09M | 6.06M | 12.77M | 33.23M |
| Cash, Cash Equivalents and Short-Term Investments | 3.71M | 1.92M | 1.44M | 3.24M | 2.40M | 4.98M |
| Total Debt | 948.00K | 1.03M | 1.05M | 1.02M | 1.28M | 1.50M |
| Total Liabilities | 4.25M | 4.01M | 2.84M | 3.05M | 6.34M | 11.90M |
| Stockholders Equity | 6.30M | 5.30M | 2.25M | 3.01M | 6.43M | 21.33M |
Cash Flow | ||||||
| Free Cash Flow | -2.59M | -3.43M | -1.70M | 845.00K | -8.49M | -20.13M |
| Operating Cash Flow | -2.24M | -3.10M | -1.66M | 1.00M | -7.74M | -12.88M |
| Investing Cash Flow | -365.00K | -1.43M | -23.00K | -156.00K | -760.00K | -7.28M |
| Financing Cash Flow | 2.65M | 5.08M | -114.00K | -7.00K | 5.92M | 20.74M |
Abingdon Health PLC Technical Analysis
Positive
11.00
Price Trends
10.37
Positive
10.82
Positive
8.87
Positive
Market Momentum
0.12
Negative
66.52
Neutral
41.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:ABDX, the sentiment is Positive. The current price of 11 is above the 20-day moving average (MA) of 10.78, above the 50-day MA of 10.37, and above the 200-day MA of 8.87, indicating a bullish trend. The MACD of 0.12 indicates Negative momentum. The RSI at 66.52 is Neutral, neither overbought nor oversold. The STOCH value of 41.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:ABDX.
Abingdon Health PLC Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | £273.56M | 39.05 | 10.14% | 2.35% | 16.51% | 97.67% | |
59 Neutral | £110.15M | 54.26 | 3.01% | 4.36% | 2.73% | -65.94% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | £27.80M | -13.10 | -55.91% | ― | 40.37% | -13.70% | |
49 Neutral | £20.87M | -1.19 | -1044.57% | ― | 65.60% | 74.84% | |
45 Neutral | £33.81M | -0.33 | -631.25% | ― | ― | ― | |
38 Underperform | £3.33M | -0.57 | -69.62% | ― | -16.27% | -471.21% |
* Healthcare Sector Average
GB:ABDX
Abingdon Health PLC
11.00
5.25
91.30%
GB:NIOX
Circassia Pharmaceuticals
66.00
-3.21
-4.64%
GB:EKF
EKF Diagnostics Holdings
25.50
-3.80
-12.97%
GB:GDR
Genedrive
1.30
0.81
163.69%
GB:CNSL
Omega Diagnostics
1.40
-1.70
-54.84%
GB:RENX
Renalytix
6.30
0.45
7.69%
Abingdon Health PLC Corporate Events
Business Operations and StrategyFinancial Disclosures
Abingdon Health posts 31% revenue rise and H2 EBITDA profitability
Positive
Jul 29, 2026
Abingdon Health PLC, a specialist in rapid diagnostic test development and manufacturing, has built an integrated CDMO and regulatory services platform that supports international customers from concept through to commercial-scale production. With...
Business Operations and Strategy
Abingdon Health to Showcase Med-Tech Services at Mello2026 Investor Conference
Positive
May 29, 2026
Abingdon Health plc, a UK-headquartered med-tech contract developer and manufacturer of lateral flow and rapid diagnostic tests with integrated regulatory and analytical services, serves global clients across medical, veterinary and environmental ...
Business Operations and Strategy
Abingdon Health Wins Wisconsin Tax Credits to Expand US Operations
Positive
May 27, 2026
Abingdon Health’s US subsidiary has secured certification for up to US$370,000 in performance-based tax credits from the Wisconsin Economic Development Corporation over three years starting in 2026. The credits are tied to job creation and c...
Business Operations and StrategyPrivate Placements and Financing
Abingdon Health issues new shares as IVDeology earn-out is fully achieved
Positive
May 19, 2026
Abingdon Health has triggered the full earn-out payment for its 2024 acquisition of regulatory services firm IVDeology after the business achieved the maximum revenue target over a two-year period. The company will settle the £200,000 conside...
Business Operations and StrategyProduct-Related Announcements
Abingdon Health backs UK launch of rapid stroke triage test LVOne
Positive
May 11, 2026
Abingdon Health plc, a specialist in contract development and manufacturing of lateral flow diagnostics, supports clients from concept through regulatory approval and routine production from facilities in York and Doncaster in the UK and Madison, ...
Business Operations and StrategyProduct-Related Announcements
Abingdon Health Advances Co-Developed Companion Diagnostic with 4TEEN4
Positive
May 6, 2026
Abingdon Health has provided a detailed update on its collaboration with German biopharmaceutical firm 4TEEN4 Pharmaceuticals to develop DPP3 InvoSelect, a lateral flow-based companion diagnostic for invobenitug, an antibody therapy targeting life...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.